Israel and Argentina are in talks to produce the coronavirus vaccine developed in the country. The vaccine, called Brilife, is based on vectors, does not cause any disease by itself and develops immune defenses, according to the Israeli Aurora site.
The Hadassah University Hospital, leader in Phase 2 clinical trials and in the rest of the development, also put its grain of sand so that this deal is carried out very soon in Argentina.
The idea is to summon Argentine volunteers to be part of the Phase 3 tests of the drug to verify its effectiveness, and to start producing it in South America, through a public and private agreement. Negotiations with Argentine Ambassador Sergio Urribarri in Israel had started last summer.
Between 30 and 40 thousand people will be needed for the last part of the inoculation process.
Due to the large volume of inhabitants immunized against the coronavirus in Israel, it is difficult to find more interested in contributing to this epidemiological study, so Argentina plays a key role in its advancement and progress to be successful.
With almost 60% of its population inoculated at least once (this equates to 9 million people), Israel took an important step on Sunday with the reopening of cafes, bars and restaurants, the return to classrooms in universities, among other restrictions relaxation measures.
Urribarri highlighted the joint work between both nations in the midst of the pandemic and the possibility of Argentina producing the Israeli vaccine at the local level. “The link between Argentina and Hadassah was one of the first tasks that I dedicated myself to when I arrived in Israel. At the initiative of our embassy, several joint actions were carried out, including the exchange between professionals from Hadassah and from our Garrahan Hospital, which is in full swing. Since then, a link has been forged with this hospital, which is among the most important in Israel and in the world, which now calls on our country to be a central actor in the development of this vaccine, ”the ambassador said.
Last March, Urribarri had met with Zeev Rothstein, general director of the Hadassah Hospital, and with Eran Zahavi, director of the Israeli Institute for Biological Research, an organization that operates under the orbit of the Israeli Ministry of Defense and that carries out the development and clinical trials of the vaccine in various hospitals.
Israel estimates that phase 2 of its vaccine will soon be successfully completed. In addition to local production, the offer made to Argentina is to carry out phase 3 of the evaluation.
“The offer they are making to us, which I have already transmitted to our president, Alberto Fernández, and to our foreign minister, is, on the one hand, the possibility of carrying out phase 3 in Argentina, for which between 24,000 and 30,000 volunteers would be required. On the other hand, they are interested in setting up a production line in Argentina, which would be the first in the world, for which it would be necessary to find an Argentine pharmaceutical company that would act as a local partner, ”Urribarri explained.
Hadassah Hospital will be the institution in charge of organizing and coordinating the tasks ahead, in conjunction with the Israeli Institute for Biological Research. The next step will be for both parties to work on the analysis of Argentine regulations to continue analyzing the possibility of approving this operation, reported from the Ministry of Foreign Relations.